Health
Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals – News-Medical.Net
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe…
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate the safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.
Opaganib potentially minimizes the likelihood of resistance due to viral mutations by targeting a human cell component involved…
-
Noosa News22 hours agoPolice appeal for information over suspected link in torture and murder cases
-
General24 hours agoAustralian picture books aim to give neurodivergent kids a better sense of self
-
Noosa News15 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General20 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline